Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Maggi

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Targeted Oncology|November 6, 2015
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal CancerFilippo Pietrantonio, Filippo de Braud, Massimo Milione, et al.
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
Journal of Translational Medicine|May 8, 2016
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational studyFilippo Pietrantonio, Rosa Berenato, Claudia Maggi, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Targeted Oncology|November 6, 2015
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal CancerFilippo Pietrantonio, Filippo de Braud, Massimo Milione, et al.
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
Journal of Translational Medicine|May 8, 2016
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational studyFilippo Pietrantonio, Rosa Berenato, Claudia Maggi, et al.
Pageof 4